Smaller medtechs suffer, but not from Covid-19
Emergence from lockdown is the driving force behind many – but not all – of the small and mid-cap share price moves.
Atricure lassoes Sentreheart for $40m
Ablation company takes on a new tech, and responsibility for an expensive clinical trial.
Ablation groups scramble to cope with Cabana
The Cabana trial has finally reported, but the data are inconclusive.